Clinical Evaluation of Patients With X-linked Retinoschisis

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
X-linked RetinoschisisXLRS
Interventions
DRUG

Dorzolamide 2% TID or brinzolamide 1% TID

"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"

Trial Locations (3)

48105

University of Michigan Kellogg Eye Center, Ann Arbor

75231

Retina Foundation of the Southwest, Dallas

97239

Casey Eye Institute, Oregon Health and Sciences University, Portland

Sponsors
All Listed Sponsors
collaborator

Foundation Fighting Blindness

OTHER

lead

Beacon Therapeutics

INDUSTRY